NCT04108091Completed
Vyndaqel Capsules Special Investigation (ATTR-CM)
Vyndaqel Capsules Special Investigation - Investigation on Patients With Transthyretin Amyloid Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
Secondary Data Collection : To confirm the safety and effectiveness profiles under the actual medical practice of Vyndaqel in Japan. This study is conducted in accordance with the protocol even when Vynmac is used, and information the use of Vynmac during the observation period is also collected.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1214 (actual)
- First submitted
- 26 Sept 2019
- Start date
- 3 Oct 2019
- Primary completion date
- 27 Mar 2025
- Lead sponsor
- Pfizer
- Diseases
- Amyloidosis
- NCT number
- NCT04108091
What you commit to
- Study type: Observational
- Participants enrolled: 1214
- From 3 Oct 2019 to the primary completion date, 27 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- N/A
Who the study is looking for
- Patients administered Vyndaqel for the treatment of ATTR-CM
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.